Paratek Pharmaceuticals, Inc.

Informe acción NasdaqGM:PRTK

Capitalización de mercado: US$127.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Paratek Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Paratek Pharmaceuticals' CEO is Evan Loh, appointed in Jun 2019, has a tenure of 4.25 years. total yearly compensation is $2.04M, comprised of 31.8% salary and 68.2% bonuses, including company stock and options. directly owns 1.87% of the company’s shares, worth $2.38M. The average tenure of the management team and the board of directors is 4.3 years and 8.9 years respectively.

Información clave

Evan Loh

Chief Executive Officer (CEO)

US$2.0m

Compensación total

Porcentaje del salario del CEO31.8%
Permanencia del CEO4.3yrs
Participación del CEO1.9%
Permanencia media de la dirección4.3yrs
Promedio de permanencia en la Junta Directiva8.9yrs

Actualizaciones recientes de la dirección

Recent updates

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Apr 17
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Paratek Pharmaceuticals: Patience Is Wearing Thin

Aug 24

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Aug 03

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

Jan 03

The Play On Paratek Pharmaceuticals

Oct 18

Peeking Back In On Paratek Pharmaceuticals

Aug 07

Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial

Jun 16

Paratek shares rise after FDA approves NUZYRA oral only dosing regimen

Jun 01

Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business

Apr 27

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Mar 01
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Feb 01
Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment

Jan 04

Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale

Dec 01

Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Evan Loh en comparación con los beneficios de Paratek Pharmaceuticals?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2023n/an/a

-US$63m

Mar 31 2023n/an/a

-US$66m

Dec 31 2022US$2mUS$650k

-US$64m

Sep 30 2022n/an/a

-US$89m

Jun 30 2022n/an/a

-US$86m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$4mUS$600k

-US$59m

Sep 30 2021n/an/a

-US$52m

Jun 30 2021n/an/a

-US$54m

Mar 31 2021n/an/a

-US$87m

Dec 31 2020US$2mUS$575k

-US$97m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$111m

Mar 31 2020n/an/a

-US$121m

Dec 31 2019US$2mUS$520k

-US$129m

Sep 30 2019n/an/a

-US$124m

Jun 30 2019n/an/a

-US$124m

Mar 31 2019n/an/a

-US$120m

Dec 31 2018US$2mUS$480k

-US$112m

Sep 30 2018n/an/a

-US$111m

Jun 30 2018n/an/a

-US$101m

Mar 31 2018n/an/a

-US$89m

Dec 31 2017US$3mUS$450k

-US$89m

Sep 30 2017n/an/a

-US$94m

Jun 30 2017n/an/a

-US$96m

Mar 31 2017n/an/a

-US$108m

Dec 31 2016US$1mUS$415k

-US$112m

Compensación vs. Mercado: Evan's total compensation ($USD2.04M) is above average for companies of similar size in the US market ($USD764.66K).

Compensación vs. Ingresos: Evan's compensation has been consistent with company performance over the past year.

CEO

Evan Loh (64 yo)

4.3yrs

Permanencia

US$2,042,511

Compensación

Dr. Evan Loh, M.D., FACC, FAHA, has been the Chief Executive Officer of Paratek Pharmaceuticals, Inc. since June 25, 2019. Dr. Loh served as Independent Director at Windtree Therapeutics, Inc. since Februa...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Michael Bigham
Executive Chairman8.9yrsUS$1.73m1.93%
$ 2.5m
Evan Loh
CEO & Director4.3yrsUS$2.04m1.87%
$ 2.4m
Adam Woodrow
President & Chief Commercial Officer4.3yrsUS$1.15m1.09%
$ 1.4m
Sarah Higgins
VP of Finance8.5yrssin datossin datos
William Haskel
Senior VP8.3yrsUS$1.25m0.62%
$ 797.8k
Jonathan Light
Deputy General Counsel & Chief Compliance Officer6.1yrssin datossin datos
Karen McGrath
Chief People Officer4.2yrssin datossin datos
Randall Brenner
Chief Development & Regulatory Officer4.3yrssin datos0.58%
$ 735.2k

4.3yrs

Permanencia media

58.5yo

Promedio de edad

Equipo directivo experimentado: PRTK's management team is considered experienced (4.3 years average tenure).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Michael Bigham
Executive Chairman8.9yrsUS$1.73m1.93%
$ 2.5m
Evan Loh
CEO & Director11.3yrsUS$2.04m1.87%
$ 2.4m
Jeffrey Stein
Lead Independent Director8.9yrsUS$147.80k0.097%
$ 124.0k
Thomas Dietz
Independent Outside Director8.9yrsUS$150.30k0.087%
$ 111.5k
Kristine Peterson
Independent Outside Director7.5yrsUS$137.80k0.10%
$ 131.6k
Timothy Franson
Independent Outside Director8.2yrsUS$135.30k0.10%
$ 131.6k
Robert Radie
Independent Outside Director8.9yrsUS$140.30k0.091%
$ 116.5k
Rolf Hoffmann
Independent Director5.4yrsUS$127.80k0.11%
$ 142.7k
Minnie Baylor-Henry
Independent Director2.3yrsUS$132.80k0.068%
$ 87.4k

8.9yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: PRTK's board of directors are considered experienced (8.9 years average tenure).